Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, BAX, or p21(WAF1/CIP1)

In Vivo

Volumn 13, Issue 1, 1999, Pages 1-6

  Digiuseppe, Joseph A ^a   Kastan, Michael B ^a   Weng, Li Jun ^a   Gore, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Apoptosis; bax; bcl 2; Growth factors; p21(WAF1 CIP1)

Indexed keywords

ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; MILODISTIM; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; STEEL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MALE; PROTEIN EXPRESSION;

EID: 0032897044     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Lotem J and Sachs L: Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia 10: 925-931, 1996.
2. Hunter A, Rogers SY, Roberts IAG, Barrett AJ and Russell N: Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 82: 899-903, 1993.
3. Lowenberg B, van Putten WL, Touw IP, Delwel R and Santini V: Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. New Engl J Med 328: 614-619, 1993.
4. Lotem J and Sachs L: Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80: 1750-1757, 1992.
5. Sachs L and Lotem J: Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 82: 15-21, 1993.
6. Kaplinsky C, Lotem J and Sachs L: Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3. Leukemia 10: 460-465, 1996.
7. Lotem J and Sachs L: Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and Bcl-2 dependent and independent pathways. Cell Growth Differ 5: 321-327, 1994.
8. Lotem J and Sachs L: Interferon-gamma inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells. Leukemia 9: 685-692, 1995.
9. Rinaudo M, Su K, Falk LA, Haldar S and Mufson RA: Human interleukin-3 receptor modulates Bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood 86: 80-88, 1995.
10. L, and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 6: 647-653, 1995.
11. Kinoshita T, Yokota T, Arai K-I and Miyajima A: Suppression of apoptotic death in hematopoietic cells by signaling through the IL-3/GM-CSF receptors. EMBO J 14: 266-275, 1995.
12. Yang E and Korsmeyer SJ: Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood 88: 386-401, 1996.
13. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A and Keating M: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79: 2246-2255, 1992.
14. Zittoun R, Suciu S, Mandelli F, De Witte T, Thaler T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC and Willemze R: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer and Leukemia Cooperative Group. J Clin Oncol 14: 2150-2159, 1996.
15. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
16. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
17. el-Deiry WS, Harper JW, O'Conner PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.Cancer Res 54: 1169-1174, 1994.
18. WAF1/CIP1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684, 1995.
19. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557, 1995.
20. 1 arrest in human cancer cells. Cancer Res 55: 5187-5190, 1995.
21. Nelson WG and Kastan, MB: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823, 1994.
22. Polyak K, Waldman T, He T-C, Kinzler KW, and Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes and Development 10: 1945-1952, 1996.
23. Wang J and Walsh K: Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science 273: 359-361, 1996.
24. WAF1 is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 16: 1335-1341, 1996.
25. WAF1/CIP1 against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol Cell Biol 16: 6654-6660, 1996.
26. Canman CE, Gilmer TM, Coutts SB and Kastan MB: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes and Development 9: 600-611, 1995.
27. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AB and Mercer WE: p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth and arrest accompanying monocyte/macrophage differentiation. Cancer Res 55: 668-674, 1995.
28. CIP1 in the maintenance of stem/progenitor cells in vivo. Blood 88: 3710-3719, 1996.
29. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D and Deisseroth AB: High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Canc Res 1: 1051-1057, 1995.
30. Imamura J, Miyoshi I and Koeffler HP: p53 in hematologic malignancies. Blood 84: 2412-2421, 1994.
31. Gore SD, Weng LJ and Burke PJ: Identification of growth factor-responsive acute myelogenous leukemia based on factor-dependence for survival and proliferation. Leukemia 8: 1854-1863, 1994.
32. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ, Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597, 1992.
33. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW and Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88: 1936-1943, 1996.
34. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M and Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12: 1055-1062, 1996.
35. Levine A, Mormand J and Finley CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
36. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
37. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
38. Reed J: Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Current Opinion in Oncology 7: 541-546, 1995.
39. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P and Guyotat D: High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091-3096, 1993.
40. DiGiuseppe J, LeBeau P, Augenbraun J and Borowitz MJ: Multiparameter flow-cytometric analysis of Bcl-2 and Fas in normal and neoplastic hematopoiesis. Am J Clin Pathol 1106: 345-351, 1996.
41. Weber-Nordt R, Henschler R, Schott F, Wehniger J, Behringer D, Mertelsmann R and Finke J: Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood 88: 2549-2558, 1996.
42. Bradbury D, Zhu Y-M, and Russell N: Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 8: 786-791, 1994.
43. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V and Andreef M: Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and bax. Blood 88: 3987-3997, 1996.
44. Zha J, Harada H, Yang E, Jockel J and Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X,. Cell 87: 619-628, 1996.
45. WAF1/CIP1 expression in the absence of p53. Oncogene 9: 3397-3406, 1994.
46. Steinman R, Hoffman B, Iro A, Guillouf C, Lieberman DA and El-Houseini ME: Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 9: 3389-3396, 1994.
47. WAF1/CIP1 in differentiating human leukemia cells. J Clin Invest 95: 973-979, 1995.